CALGARY, July 25, 2017 /PRNewswire/ - Resverlogix
Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today
that it filed its audited Consolidated Financial Statements for the
year ended April 30, 2017 and related
Management's Discussion and Analysis with Canadian securities
regulatory authorities. The Company has also filed its Annual
Information Form for the year ended April
30, 2017. Copies of these documents may be obtained online
at www.sedar.com, or the Company's website, www.resverlogix.com, or
by emailing ir@resverlogix.com. An additional corporate financial
update will take place prior to August
28th, 2017.
Resverlogix to Host Symposium at the European Society of
Cardiology Congress 2017
The Company also announced today that on Saturday, August 26, 2017, at the European
Society of Cardiology (ESC) Congress in Barcelona, Spain, it will host a symposium
titled: "Managing Diabetes & CVD: Is epigenetics a new way
forward?"
The agenda and speakers are as follows:
Introduction
Lina Badimon, MD – Barcelona, Spain
Managing high risk diabetes patients with cardiovascular
disease: What works, and what else can we do? - Kausik Ray, MD - Imperial College London, United Kingdom
Promise of epigenetic modulation as a target in
atherosclerotic patients
- Erik
Stroes, MD - Academic Medical Centre, Amsterdam, Netherlands
Insights from the first trials in epigenetics in human: What
is the way forward?
- Stephen
Nicholls, MD - Adelaide,
Australia
Presentations will be made available at: www.pace-cme.org.
Mr. Donald McCaffrey, President
and CEO commented, "The presentations at the ESC Congress symposium
will highlight apabetalone and its opportunity as a novel approach
to the treatment of high-risk cardiovascular disease in patients
with diabetes. Data to be presented demonstrates the important role
for epigenetics in the underlying pathology of these diseases." Mr.
McCaffrey added, "Importantly, we remain encouraged by the recent
data safety monitoring board review and recommendation to once
again continue with the Phase 3 BETonMACE trial as planned. The
trial has already enrolled over 70 percent of the planned 2,400
patients and remains on track with internal projections."
Resverlogix will also present two posters at the congress
titled:
i)
|
"Lowering the
neutrophil to lymphocyte ratio by the BET inhibitor, apabetalone:
potential implications for cardiovascular events in high risk
patients"
|
|
|
|
Poster Presentation
Details:
|
|
|
|
Date: Sunday, August
27, 2017
|
|
Time: 9:30am –
10:45am CET
|
|
Session number:
302
|
|
Session title: Poster
Session 2
|
|
|
ii)
|
"Apabetalone
(RVX-208) impacts key biomarkers and pathways associated with
cardiovascular disease in patients with severe renal
impairment"
|
|
|
|
Poster Presentation
Details:
|
|
|
|
Date: Tuesday, August
29, 2017
|
|
Time: 3:30pm – 4:30pm
CET
|
|
Session number:
307
|
|
Session title: Poster
Session 7
|
The posters will be made available HERE on the Company's website
at the time of their respective presentation dates and times at the
congress.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a
first-in-class, small molecule that is a selective BET (bromodomain
and extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease (CVD), diabetes
mellitus (DM), chronic kidney disease, end-stage renal disease
treated with hemodialysis, neurodegenerative disease, Fabry
disease, peripheral artery disease and other orphan diseases, while
maintaining a well described safety profile. Apabetalone is the
only selective BET bromodomain inhibitor in human clinical trials.
Apabetalone is currently being studied in a Phase 3 trial,
BETonMACE, in high-risk CVD patients with type 2 DM and low
high-density lipoprotein (HDL), and is expected to be initiated in
a Phase 2a kidney dialysis trial designed to evaluate biomarker
changes and safety parameters in up to 30 patients with end-stage
renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on
our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to the potential role of apabetalone in the
treatment of CVD, DM, chronic kidney disease, end-stage renal
disease treated with hemodialysis, neurodegenerative disease, Fabry
disease, peripheral artery disease and other orphan diseases. Our
actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous assumptions and
risk factors including those discussed in our Annual Information
Form and most recent MD&A which are incorporated herein by
reference and are available through SEDAR at www.sedar.com. The
forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
SOURCE Resverlogix Corp.